Therapeutics to prevent aminoglycoside-induced hearing loss
Therapeutics to prevent aminoglycoside-induced hearing loss
批准号:
10081937
负责人:
Marisa L. Zallocchi
金额:
$24.23万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-17 至 2022-01-31
关键词:
AdjuvantAdultAffectAlkaloidsAminoglycosidesAnimal ModelAnimalsAntibioticsAntidiabetic DrugsAntifungal AgentsAntioxidantsAuditory Brainstem ResponsesAuditory ThresholdBacterial InfectionsBlood - brain barrier anatomyC57BL/6 MouseCapsicumCell DeathCisplatinCochleaDevelopmentDiseaseDiureticsDoseEmbryoEquilibriumFibroblastsFutureGentamicinsGlutathione Metabolism PathwayGoalsGram-Negative Bacterial InfectionsHair CellsHealthHearingHearing TestsHistologyIn VitroInfectionInflammationJaborandi PepperKanamycinLightMeasuresMorphologyMusNatural ProductsNeomycinNoiseOrgan of CortiPatientsPharmaceutical PreparationsPhasePresbycusisPreventionPropertyQuinoxalinesSocietiesStria VascularisTestingTherapeuticTimeToxic effectUnited States Food and Drug AdministrationWorkWorld Health OrganizationZebrafishaminoglycoside-induced ototoxicityanti-canceranticancer activityauditory threshold shiftbactericidebasecancer therapycell injurychemotherapycisplatin induced hearing losscombatcytotoxicitydrug candidateefficacy testinghearing impairmenthigh throughput screeningin vivoin vivo Modelintraperitoneallateral linemouse modelneuromastnovel therapeuticsotoacoustic emissionotoprotectantpermanent hearing losspre-clinicalpreclinical trialpreservationpreventprotective effectside effectsmall molecule librariessodium thiosulfatespiral ganglionsubcutaneousvitamin metabolism
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Hearing loss is a major health concern in our society, affecting over 360 million people worldwide
(World Health Organization, 2017). Aminoglycoside chemotherapy causes permanent hearing loss in
20-25% of treated patients. To date, no drugs have been approved by the Food and Drug
Administration for protection from aminoglycoside-related hearing loss. Most candidate compounds
currently in pre-clinical trials are related to antioxidants, vitamins, and glutathione metabolism, and
thus many of these compounds, such as sodium thiosulfate, can interfere with aminoglycoside
bactericidal activity.
We have conducted a high-throughput screen of bioactive synthetic and natural compounds
employing zebrafish as our platform for aminoglycoside ototoxicity and identified a natural compound
as an important therapeutic molecule for aminoglycoside-induced cell death and hearing loss.
Our Specific Aim is to test whether this natural compound protects from aminoglycoside-induced
hearing loss by systemic delivery in a mouse model. Our approach is to intraperitoneally administer
the compound for 15 days in adult C57BL/6 mice treated with kanamycin, measure their ABR and
DPOAEs thresholds, EPs and analyze their cochlear histology. The maximum non-toxic dose of this
compound will be experimentally determined and tested for hearing-protective effects. This work will
shed light on the possibility of using this natural compound to combat aminoglycoside-induced
hearing loss.
The results of this study will provide the key proof of principle to develop novel therapeutic strategies
against side effects of aminoglycoside chemotherapy. In the future, we will also test the efficacy of
this compound to protect against cisplatin- noise- and age-related hearing loss. If successful, this
proposal, has the potential to be a significant step forward for the treatment of aminoglycoside-
induced hearing loss in patients suffering from severe Gram-negative bacterial infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification and characterization of novel functions for the Usher proteins in the inner ear
-
批准号:10677948
-
项目类别:
-
资助金额:$52.01万
-
财政年份:2023
-
负责人:Marisa L. Zallocchi
-
依托单位:
CDK2 inhibitors for protecting hearing loss
-
批准号:10382178
-
项目类别:
-
资助金额:$56.62万
-
财政年份:2019
-
负责人:Marisa L. Zallocchi
-
依托单位:
CDK2 inhibitors for protecting hearing loss
-
批准号:9907921
-
项目类别:
-
资助金额:$22.07万
-
财政年份:2019
-
负责人:Marisa L. Zallocchi
-
依托单位:
海外基金